Nuclera key facts
as of Oct 2026- Developer of a protein prototyping system designed to accelerate drug discovery workflows.
- Nuclera is valued at approximately $154.5M as of Oct 2026, set at its Series B, Jul 2022; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $166.1M across 9 recorded rounds; the latest was Later Stage VC (Series C) ($87.0M) in Jan 2026.
- Notable investors include Innovate UK, Tech Nation Group, Puhua Capital, British Business Bank, Future Planet Capital — 22 tracked in total.
- Status: Privately Held (backing).
Valued at $154.5M at its Series B, Jul 2022. Nothing has traded since.
- ·Post-money valuations for 2 rounds
- ·The complete investor list: 22 names
- ·Watch Nuclera: the Monday email on marks, rounds and moves
Nuclera funding rounds
9 roundsNuclera leadership
- Michael Chen Ph.DCo-Founder, Chief Executive Officer & Board Member
- Seth BensonChief Financial Officer
- Gordon McInroy Ph.DCo-Founder, Chief Operating Officer & Board Member
- Joseph BertelsenChief Commercial Officer
Who backs Nuclera
22+Nuclera valuation
Nuclera was valued at $155 million at its Series B in Jul 2022. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Nuclera raised?
Nuclera has raised $166 million across 9 recorded rounds since 2014. The largest was an $87 million Series C in Jan 2026. 2 of the rounds disclosed a post-money valuation.
Nuclera investors
22 investors are on record for Nuclera, including Innovate UK, Tech Nation Group, Puhua Capital and British Business Bank. By type, the record holds 4 venture capital firms and 1 asset manager. The Series C in Jan 2026 drew 11 investors.
Who runs Nuclera
11 people are listed on the Nuclera team: 5 executives and 6 board members, including Gordon McInroy Ph.D (Co-Founder) and Michael Chen Ph.D (Co-Founder). 7 of them have a verified direct contact on file.
About Nuclera
Developer of a protein prototyping system designed to accelerate drug discovery workflows. The company's system helps construct design, expression, solubility characterization, and purification of target proteins in drug discovery programs and allows screening and synthesizing proteins on terms and bench, enabling healthcare professionals with integrated cell-free protein synthesis and digital microfluidics on smart cartridges.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2013
- Employees
- 134
- Website
- nuclera.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.